Video

Treatments for Relapsed Mantle Cell Lymphoma

Most patients with mantle cell lymphoma (MCL) will experience a recurrence, states Brad S. Kahl, MD. A next-line treatment option for relapsed disease is ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, which is well tolerated and has response rates of more than 70%. However, most patients will progress while on ibrutinib and may be given lenalidomide plus rituximab, which has response rates closer to 60% after recurrence. Another option is bortezomib, which has shown response rates of 33%.

When MCL evolves from a low-grade lymphoma to a blastic variant, the disease becomes difficult to control and requires different therapies, says Richard R. Furman, MD. Low-grade variants respond well to therapies like ibrutinib, lenalidomide, and bortezomib, but the efficacy of these agents is limited by the development of resistance and transformation.

Ibrutinib is dosed at 560 mg daily and is typically given until disease progression or intolerance. While patients tend to experience a benefit within days of starting therapy, it may take months to achieve maximal remission, says Kahl. Toxicities include diarrhea, muscle ache, arthralgia, fatigue, and a small risk of bleeding.

Mechanisms of resistance to ibrutinib include those that prevent ibrutinib from binding to BTK. In these patients, ibrutinib is converted from an irreversible inhibitor to a reversible inhibitor and loses efficacy, explains Furman. Moving ibrutinib to an earlier line of therapy before patients are exposed to chemotherapy may help, says Furman, as it increases the likelihood of using ibrutinib before the development of blastic disease.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity